Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
Celyad Oncology (symbol: CYAD) is a clinical-stage biopharmaceutical company founded in 2007. The company is renowned for its expertise in cell-based therapies, particularly in taking them from the initial research phase to Phase III clinical trials. Celyad boasts robust manufacturing and logistical infrastructure designed to support the development of complex cell-based products.
Celyad's business model is rooted in strategic partnerships with esteemed research institutions such as Dartmouth College. These collaborations are instrumental in advancing their innovative programs from bench research to commercial applications.
One of the company's major focus areas is immuno-oncology, where it is pioneering the development of natural killer receptor T-cells (NKR-T cells) aimed at treating cancer. This unique therapeutic approach has shown promise in targeting and potentially destroying a wide variety of tumor types, positioning Celyad at the forefront of cancer treatment innovation.
Listed on Euronext Brussels, Euronext Paris, and NASDAQ under the ticker symbol CYAD, Celyad continues to gain recognition for its groundbreaking work in the biotech industry. The financial condition of the company is robust, with ongoing projects that underscore its commitment to transforming cancer care. Recent achievements and current projects reflect a steadfast dedication to clinical excellence and innovation.
Celyad Oncology (Euronext & Nasdaq: CYAD) announced the acceptance of two abstracts for presentation at the 63rd American Society of Hematology (ASH) Annual Meeting, scheduled for December 11-14, 2021, in Atlanta, Georgia. The presentations will focus on:
- CYAD-211 for relapsed/refractory multiple myeloma (poster presentation)
- CYAD-02 for relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes (oral session)
Both abstracts will also be published in the November issue of the journal Blood.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced its virtual participation in the Jefferies London Healthcare Conference on November 18-19, 2021. The company focuses on developing chimeric antigen receptor T cell (CAR T) therapies for cancer, including allogeneic and autologous candidates for hematological malignancies and solid tumors. Founded in 2007 and based in Belgium and New York, Celyad has received funding from the Walloon Region to support its CAR T cell programs. Investors are advised to review potential risks in the forward-looking statements in the release.
Celyad Oncology announced a capital increase of 300,000 new shares to Lincoln Park Capital Fund, LLC, boosting its share capital to 55,964,224.33 EUR across 16,093,956 shares. The company is focused on developing CAR T cell therapies for cancer. This move is part of a strategic effort to enhance financial capacity, which may impact shareholders by adding liquidity but could also dilute existing shares. The adjustment in capital structure is disclosed per Belgian regulations.
Celyad Oncology SA announced that three abstracts related to its allogeneic CAR T therapy programs will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 10-14, 2021. The presentations include insights on the company’s multiplexing capabilities using short hairpin RNA technology, its first allogeneic CAR T candidate CYAD-203, and the Phase 1b KEYNOTE-B79 trial of CYAD-101 for metastatic colorectal cancer patients. These findings highlight Celyad's advancements in CAR T therapies.
Celyad Oncology SA (Brussels:CYAD) announced its participation in several conferences in September 2021, including the Wells Fargo Virtual Healthcare Conference, H.C. Wainwright Global Investment Conference, and Baird’s Virtual Global Healthcare Conference. CEO Filippo Petti will present at these events, highlighting the company's focus on developing CAR T cell therapies for cancer. Celyad is based in Belgium and has received funding from the Walloon Region to support its initiatives. Further details can be found on their website.
Celyad Oncology announced updates on its clinical trials and financial results for Q2 2021. Enrollment is ongoing for the Phase 1 IMMUNICY-1 trial of CYAD-211 for relapsed/refractory multiple myeloma, with a clinical update expected by year-end. The Phase 1b KEYNOTE-B79 trial for CYAD-101 and KEYTRUDA is set to begin Q4 2021. Financially, the company reported a net loss of €14.9 million for H1 2021, improved from €16.6 million in H1 2020, with cash reserves of €12 million. The company remains optimistic about upcoming milestones.
Celyad Oncology, a clinical-stage biotechnology company, announced a capital increase of 300,000 new shares on July 30, 2021, to Lincoln Park Capital Fund, LLC. This move raises the company's share capital to 54,956,224.33 EUR, represented by 15,793,956 shares. Following the capital increase, the total number of diluted shares stands at 17,716,379. The company focuses on developing CAR T therapies for cancer treatment and is headquartered in Belgium.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) will report its first half 2021 financial and operating results on August 4, 2021. A conference call is scheduled for August 5 at 2 p.m. CEST / 8 a.m. EDT to discuss these findings and updates on recent progress. Celyad focuses on developing CAR T therapies for cancer, including both allogeneic and autologous candidates, supported by funding from the Walloon Region, Belgium. The company warns that forward-looking statements may involve risks, including those associated with the COVID-19 pandemic.
Celyad Oncology (CYAD) provided updates on its CAR T therapies during a recent research and development day. The Phase 1 IMMUNICY-1 trial of CYAD-211 for relapsed/refractory multiple myeloma showed promising dose-dependent engraftment with no reported Graft-versus-Host disease. The IND application for CYAD-203, a first-in-class IL-18-armored CAR T candidate, is expected by mid-2022. Additionally, CYAD-101 demonstrated good tolerability in advanced metastatic colorectal cancer and will soon enter the KEYNOTE-B79 Phase 1b trial. The company also acquired a license for an antibody targeting TAG-72.
Celyad Oncology announced a Research & Development webinar on July 20th, 2021, at 11:30 a.m. EDT, focusing on advancements in its pipeline. The leadership team will discuss preclinical allogeneic CAR T assets using shRNA technology and updates on clinical programs, including the CYAD-211 candidate for relapsed/refractory multiple myeloma and CYAD-101 for metastatic colorectal cancer. Investors can register for the live webcast on the Celyad website, with a replay available afterward.
FAQ
What is the market cap of CYAD (CYAD)?
What does Celyad Oncology specialize in?
When was Celyad Oncology founded?
On which stock exchanges is Celyad listed?
What is the company's ticker symbol?
Who are Celyad's key research partners?
What are natural killer receptor T-cells (NKR-T cells)?
What is Celyad's business model?
What are some recent achievements of Celyad Oncology?
What is the status of Celyad's financial condition?
How can I stay updated on Celyad's latest news?
